CAR-T Cell Therapy for International Patients

A celebration is underway in the CAR-T ward at Shanghai Yaoying Hospital. Dale, a patient from New Zealand, accepts a cake prepared by the Yaoying medical team—topped with a small “1” candle, symbolizing the beginning of a brand-new chapter in his life.

Dale’s case was exceptionally complex and challenging: he presented with primary refractory, high-risk “double-hit” lymphoma—a relapsed, treatment-resistant, high-risk form of the disease that had failed to respond to three prior lines of chemotherapy. Yaoying Medical achieved the first successful remission in his case. Meanwhile, Tim, a 72-year-old patient from the United Kingdom suffering from multiple myeloma, was also discharged successfully two weeks after completing his CAR-T cell therapy at the hospital. As a representative of high-quality healthcare in Shanghai, Yaoying Medical has reached a significant milestone in the field of innovative cancer therapies, with several international patients successfully undergoing CAR-T cell treatment and subsequently being discharged. Follow-up assessments indicate that these patients are showing strong recovery across all clinical indicators.

“Shanghai Yaoying Hospital has established a mature CAR-T cell therapy platform, supported by a comprehensive multidisciplinary hematology team. We are able to provide personalized, integrated anti-tumor treatments—including CAR-T therapy—for patients with various hematological malignancies, such as multiple myeloma and diffuse large B-cell lymphoma,” says Dr. Zhou Lili, Director of the Hematology Department at Yaoying Medical. She notes that since the hospital began offering CAR-T therapy, many international patients have sought consultations and successfully completed their treatment.

CAR-T cell therapy—short for chimeric antigen receptor T-cell immunotherapy—stands at the forefront of modern cancer treatment. China is now widely recognized as a global leader in this field. High-quality healthcare providers like Yaoying Medical are combining international service standards with advanced diagnostic and therapeutic technologies to build a world-class brand for CAR-T cell therapy, increasingly attracting patients from abroad. This serves as a compelling microcosm of the flourishing international healthcare sector in China and the country’s growing global influence in medicine. The advent of CAR-T therapy has offered a renewed “hope for life” to countless patients who were once effectively given a “death sentence.” As a prominent, high-quality medical institution in Shanghai, Raffles Medical (Shanghai) has consistently kept a close watch on the frontiers of medicine, remaining steadfast in its commitment to delivering the greatest possible benefits to patients. With the maturation of CAR-T therapy, the organization has actively prepared to offer these services.

Under the leadership of Dr. Zhou Lili, Director of the Department of Hematology—who possesses extensive experience in CAR-T treatment—Raffles Medical (Shanghai) has established a dedicated CAR-T treatment ward and a multidisciplinary CAR-T care team, creating an international-standard platform for CAR-T therapy.

“As a cutting-edge, world-class technology, CAR-T cell therapy requires seamless collaboration across multiple medical disciplines throughout the hospital,” explains Dr. Zhou. Leveraging the strength of its various sub-specialties, Raffles Medical (Shanghai) conducts multidisciplinary consultations to develop personalized treatment plans tailored to each patient’s specific medical condition, physical health, and psychological state. “Through comprehensive pre-admission assessments, rigorous post-infusion monitoring, and continuous multidisciplinary collaboration, we ensure the smooth delivery of CAR-T therapy, helping patients safely navigate potential adverse reactions and achieve long-term disease control.”

Recognizing that international patients often travel great distances from home to seek care at Raffles Medical (Shanghai), the organization places a strong emphasis on the overall patient experience. To this end, a specialized “CAR-T Rapid Response Team” has been formed. Led by Medical Director Shen Hua, this team integrates the Department of Hematology with various other departments—including Internal Medicine, Inpatient Services, the ICU, Nursing, Laboratory, Radiology, Pharmacy, Patient Services, and Insurance. Furthermore, by collaborating with experts from public institutions such as the Ruijin Hospital Medical Consortium and the Tongji CAR-T Alliance, the team has developed comprehensive emergency protocols. This ensures that any issues are addressed and coordinated immediately, helping patients safely overcome the various challenges they may face during their treatment journey.

Leave a reply